Parkinson's disease (PD) is a neurodegenerative disease caused by loss of dopaminergic
neurons in the midbrain. PD is clinically characterized by a variety of motor and nonmotor …

Identifying biomarkers which can be used as a diagnostic tool is a major objective of
pharmacogenetic studies. Most mental and many neurological disorders have a compiled …

The association between dopamine D3 receptor (DRD3) Ser9Gly polymorphism and
treatment response to antipsychotic drugs (APDs) in schizophrenia (SCZ) has been widely …

Olanzapine is an atypical antipsychotic drug that has been increasingly used for treatment in
schizophrenia. It has been observed that olanzapine responses in schizophrenia patients …

Antipsychotic-induced akathisia (AIA) is a movement disorder characterized by a subjective
feeling of inner restlessness or nervousness with an irresistible urge to move, resulting in …

Introduction: Schizophrenia is a debilitating illness with a chronic impact on social function
and daily living. Although various antipsychotics are available, there are still many …

Associations of serotonin 2A receptor (5-HTR2A) gene polymorphisms with clinical
response to atypical antipsychotics (AAPs) treatment in schizophrenia (SCZ) were …

Background Catechol-O-methyltransferase (COMT) contributes to the control of synaptic
dopamine (DA) transmission by catalyzing DA degradation in the presynaptic space. The …

Approximately one in five individuals in the United States experiences mental health issues
in any given year, and these disorders are consistently among the leading causes of years …

Introduction. Drug-induced dyskinesia is an iatrogenic undesirable side reaction from the
extrapyramidal system that occurs during the administration of drugs, most often …